This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Syngene board to consider Q2 FY27 results on Oct 27
SYNGENE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Smallcap 250 and 0.5 pts more than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Syngene International has informed BSE that its Board of Directors will meet on Tuesday, October 27, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026. The trading window for dealing in company securities is closed for all insiders from October 1, 2026 until the close of trading hours on October 29, 2026. An analyst and investor conference call is scheduled for October 28, 2026.
Q2 and H1 results expected on Oct 27; insider trading window closed till Oct 29. Watch for earnings and management commentary.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹832.7 Cr | ₹910.6 Cr | −8.6% |
| Operating profit | ₹25.70 Cr | ₹69.80 Cr | −63.2% |
| Profit after tax | ₹32.20 Cr | ₹67.10 Cr | −52.0% |
| EBITDA margin | 16.9% | 21.9% | −5.0 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.